Page 1988 - Williams Hematology ( PDFDrive )

1962 Part XII: Hemostasis and Thrombosis Chapter 114: Control of Coagulation Reactions 1963

124. Vu TK, Hung DT, Wheaton VI, Coughlin SR: Molecular cloning of a functional 159. Pellequer JL, Gale AJ, Griffin JH, Getzoff ED: Homology models of the C domains of
thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell blood coagulation factors V and VIII: A proposed membrane binding mode for FV and
64(6):1057–1068, 1991. FVIII C2 domains. Blood Cells Mol Dis 24(4):448–461, 1998.
125. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, et al: Protease-activated receptors 1 and 4 160. Autin L, Steen M, Dahlbäck B, Villoutreix BO: Proposed structural models of the
mediate activation of human platelets by thrombin. J Clin Invest 103(6):879–887, 1999. prothrombinase (FXa-FVa) complex. Proteins 63(3):440–450, 2006.
126. Coughlin SR: Thrombin signaling and protease-activated receptors. Nature 407(6801): 161. Adams TE, Hockin MF, Mann KG, Everse SJ: The crystal structure of activated protein
258–264, 2000. C-inactivated bovine factor Va: Implications for cofactor function. Proc Natl Acad Sci U
127. Macfarlane SR, Seatter MJ, Kanke T, et al: Proteinase-Activated Receptors. Pharmacol S A 101(24):8918–8923, 2004.
Rev 53(2):245–282, 2001. 162. Lechtenberg BC, Murray-Rust TA, Johnson DJ, et al: Crystal structure of the prothrom-
128. Steinhoff M, Buddenkotte J, Shpacovitch V, et al: Proteinase-activated receptors: binase complex from the venom of Pseudonaja textilis. Blood 122(16):2777–2783, 2013.
Transducers of proteinase-mediated signaling in inflammation and immune response. 163. Lee CJ, Wu S, Pedersen LG: A proposed ternary complex model of prothrombinase
Endocr Rev 26(1):1–43, 2005. with prothrombin: Protein-protein docking and molecular dynamics simulations.
129. Leger AJ, Covic L, Kuliopulos A: Protease-activated receptors in cardiovascular dis- J Thromb Haemost 9(10):2123–2126, 2011.
eases. Circulation 114(10):1070–1077, 2006. 164. Camire RM, Kalafatis M, Tracy PB: Proteolysis of factor V by cathepsin G and elastase
130. Traynelis SF, Trejo J: Protease-activated receptor signaling: New roles and regulatory indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa
mechanisms. Curr Opin Hematol 14(3):230–235, 2007. binding. Biochemistry 37(34):11896–11906, 1998.
131. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, et al: PAR3 is a cofactor for PAR4 activa- 165. Steen M, Dahlbäck B: Thrombin-mediated proteolysis of factor V resulting in
tion by thrombin. Nature 404(6778):609–613, 2000. gradual B-domain release and exposure of the factor Xa-binding site. J Biol Chem
132. Sidhu TS, French SL, Hamilton JR: Differential signaling by protease-activated recep- 277(41):38424–38430, 2002.
tors: Implications for therapeutic targeting. Int J Mol Sci 15(4):6169–6183, 2014. 166. Toso R, Camire RM: Removal of B-domain sequences from factor V rather than spe-
133. Hollenberg MD, Mihara K, Polley D, et al: Biased signalling and proteinase-activated cific proteolysis underlies the mechanism by which cofactor function is realized. J Biol
receptors (PARs): Targeting inflammatory disease. Br J Pharmacol 171(5):1180–1194, Chem 279(20):21643–21650, 2004.
2014. 167. Thorelli E, Kaufman RJ, Dahlbäck B: Cleavage requirements for activation of factor V
134. Bahou WF: Protease-activated receptors. Curr Top Dev Biol 54:343–369, 2003. by factor Xa. Eur J Biochem 247(1):12–20, 1997.
135. Austin KM, Covic L, Kuliopulos A: Matrix metalloproteases and PAR1 activation. 168. Camire RM: A new look at blood coagulation factor V. Curr Opin Hematol 18(5):
Blood 121(3):431–439, 2013. 338–342, 2011.
136. Comp PC, Jacocks RM, Ferrell GL, Esmon CT: Activation of protein C in vivo. J Clin 169. Bos MH, Camire RM: A bipartite autoinhibitory region within the B-domain sup-
Invest 70(1):127–134, 1982. presses function in factor V. J Biol Chem 287(31):26342–26351, 2012.
137. Hanson SR, Griffin JH, Harker LA, et al: Antithrombotic effects of thrombin-induced 170. Fay PJ: Regulation of factor VIIIa in the intrinsic factor Xase. Thromb Haemost
activation of endogenous protein C in primates. J Clin Invest 92(4):2003–2012, 1993. 82(2):193–200, 1999.
138. Lentz SR, Fernandez JA, Griffin JH, et al: Impaired anticoagulant response to infusion 171. Marlar RA, Kleiss AJ, Griffin JH: Mechanism of action of human activated protein C, a
of thrombin in atherosclerotic monkeys associated with acquired defects in the protein thrombin dependent anticoagulant enzyme. Blood 59:1067–1072, 1982.
C system. Arterioscler Thromb Vasc Biol 19(7):1744–1750, 1999. 172. Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS: Proteolytic inactivation of
139. Snow TR, Deal MT, Dickey DT, Esmon CT: Protein C activation following coronary human factor VIII procoagulant protein by activated human protein C and its analogy
artery occlusion in the in situ porcine heart. Circulation 84(1):293–299, 1991. with factor V. Blood 63(2):486–489, 1984.
140. Macko RF, Killewich LA, Fernández JA, et al: Brain-specific protein C activation during 173. Kalafatis M, Rand MD, Mann KG: The mechanism of inactivation of human factor
carotid artery occlusion in humans. Stroke 30(3):542–545, 1999. V and human factor Va by activated protein C. J Biol Chem 269(50):31869–31880,
141. Petaja J, Pesonen E, Fernandez JA, et al: Cardiopulmonary bypass and activation of 1994.
antithrombotic plasma protein C. J Thorac Cardiovasc Surg 118(3):422–429, 1999. 174. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously
142. Gruber A, Pal A, Kiss RG, et al: Generation of activated protein C during thrombolysis. unrecognized mechanism characterized by poor anticoagulant response to activated
Lancet 342(8882):1275–1276, 1993. protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A
143. Macko RF, Ameriso SF, Gruber A, et al: Impairments of the protein C system and 90(3):1004–1008, 1993.
fibrinolysis in infection-associated stroke. Stroke 27(11):2005–2011, 1996. 175. Bertina RM, Koeleman BPC, Koster T, et al: Mutations in blood coagulation factor V
144. Conard J, Bauer KA, Gruber A, et al: Normalization of markers of coagulation activa- associated with resistance to activated protein C. Nature 369(6475):64–67, 1994.
tion with a purified protein C concentrate in adults with homozygous protein C defi- 176. Greengard JS, Sun X, Xu X, et al: Activated protein C resistance caused by Arg506Gln
ciency. Blood 82(4):1159–1164, 1993. mutation in factor Va. Lancet 343(8909):1361–1362, 1994.
145. Taylor FB Jr, Peer GT, Lockhart MS, et al: Endothelial cell protein C receptor plays an 177. Sun X, Evatt B, Griffin JH: Blood coagulation factor Va abnormality associated with
important role in protein C activation in vivo. Blood 97(6):1685–1688, 2001. resistance to activated protein C in venous thrombophilia. Blood 83(11):3120–3125,
146. Ishii H, Salem HH, Bell CE, et al: Thrombomodulin, an endothelial anticoagulant pro- 1994.
tein, is absent from the human brain. Blood 67(2):362–365, 1986. 178. Zivelin A, Griffin JH, Xu X, et al: A single genetic origin for a common Caucasian risk
147. Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP: Transcriptional expression of factor for venous thrombosis. Blood 89(2):397–402, 1997.
tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal 179. Zivelin A, Mor-Cohen R, Kovalsky V, et al: Prothrombin 20210G>A is an ancestral
human tissues. Thromb Haemost 82:1047–1052, 1999. prothrombotic mutation that occurred in whites approximately 24,000 years ago. Blood
148. Wong VL, Hofman FM, Ishii H, Fisher M: Regional distribution of thrombomodulin in 107(12):4666–4668, 2006.
human brain. Brain Res 556(1):1–5, 1991. 180. Heeb MJ, Kojima Y, Greengard JS, Griffin JH: Activated protein C resistance: Molecular
149. Hackeng TM, Tans G, Koppelman SJ, et al: Protein C activation on endothelial cells by mechanisms based on studies using purified Gln506-factor V. Blood 85(12):3405–3411,
prothrombin activation products generated in situ: Meizothrombin is a better protein 1995.
C activator than alpha-thrombin. Biochem J 319(Pt 2):399–405, 1996. 181. Rosing J, Hoekema L, Nicolaes GAF, et al: Effects of protein S and factor Xa on peptide
150. Varadi K, Philapitsch A, Santa T, Schwarz HP: Activation and inactivation of human bond cleavages during inactivation of factor Va and factor Va R506Q by activated pro-
protein C by plasmin. Thromb Haemost 71(5):615–621, 1994. tein C. J Biol Chem 270(46):27852–27858, 1995.
151. Haley PE, Doyle MF, Mann KG: The activation of bovine protein C by factor Xa. J Biol 182. Gale AJ, Xu X, Pellequer JL, et al: Interdomain engineered disulfide bond permitting
Chem 264(27):16303–16310, 1989. elucidation of mechanisms of inactivation of coagulation factor Va by activated protein
152. Rezaie AR: Rapid activation of protein C by factor Xa and thrombin in the presence of C. Protein Sci 11(9):2091–2101, 2002.
polyanionic compounds. Blood 91(12):4572–4580, 1998. 183. Rosing J, Bakker HM, Thomassen MC, et al: Characterization of two forms of human
153. Shim K, Zhu H, Westfield LA, Sadler JE: A recombinant murine meizothrombin pre- factor Va with different cofactor activities. J Biol Chem 268(28):21130–21136, 1993.
cursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid 184. Nicolaes GAF, Villoutreix BO, Dahlbäck B: Partial glycosylation of Asn2181 in human
artery injury. Blood 104(2):415–419, 2004. factor V as a cause of molecular and functional heterogeneity. Modulation of glycosy-
154. Slungaard A, Fernández JA, Griffin JH, et al: Platelet factor 4 enhances generation of lation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation.
activated protein C in vitro and in vivo. Blood 102(1):146–151, 2003. Biochemistry 38(41):13584–13591, 1999.
155. Slungaard A, Key NS: Platelet factor 4 stimulates thrombomodulin protein C-activating 185. Fernández JA, Hackeng TM, Kojima K, Griffin JH: The carbohydrate moiety of factor V
cofactor activity. A structure-function analysis. J Biol Chem 269(41):25549–25556, 1994. modulates inactivation by activated protein C. Blood 89(12):4348–4354, 1997.
156. Kowalska MA, Zhao G, Zhai L, et al: Modulation of protein C activation by histones, 186. Fisher M, Fernández JA, Ameriso SF, et al: Activated protein C resistance in ischemic
platelet factor 4, and heparinoids: New insights into activated protein C formation. stroke not due to factor V arginine506—>glutamine mutation. Stroke 27(7):1163–1166,
Arterioscler Thromb Vasc Biol 34(1):120–126, 2014. 1996.
157. Kowalska MA, Rauova L, Poncz M: Role of the platelet chemokine platelet factor 4 187. de Visser MCH, Rosendaal FR, Bertina RM: A reduced sensitivity for activated protein
(PF4) in hemostasis and thrombosis. Thromb Res 125(4):292–296, 2010. C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood
158. Fernandez JA, Petaja J, Gruber A, Griffin JH: Activated protein C correlates inversely 93(4):1271–1276, 1999.
with thrombin levels in resting healthy individuals. Am J Hematol 56(1):29–31, 1997. 188. Rodeghiero F, Tosetto A: Activated protein C resistance and factor V Leiden mutation
are independent risk factors for venous thromboembolism. Ann Intern Med Intern Med
130(8):643–650, 1999.

Kaushansky_chapter 114_p1949-1966.indd 1963 9/18/15 10:06 AM